UK’s Food Standards Agency Begins Processing CBD Applications
The UK’s de facto CBD regulator has begun approving CBD food products for sale.
Nevada Considers Removing Label Requirement for Radiation-Treated Cannabis
The Nevada Cannabis Compliance Board (CCB) are considering changes to its state cannabis regulations which would remove the requirement for cannabis treated with irradiation to display the international symbol for irradiation, the Radura.
Oklahoma Cannabis Testing Lab Loses License
State authorities in Oklahoma have revoked the license of a medical cannabis testing lab on the grounds of public health and safety.
Cannabis Users With Genetic Markers for Schizophrenia Are More Likely to Have Psychotic Episodes, Study Finds
The paper found that, while cannabis consumers have higher rates of psychotic experiences than non-consumers, the difference was indeed more pronounced among those with a high genetic predisposition to schizophrenia.
New Research Sheds Light on How Long Cannabis Impairment Lasts
In a new meta-analysis of past cannabis impairment studies, researchers at the University of Sydney have identified a “window of impairment” following medium and high-dose cannabis use, during which users should avoid driving.
Psilocybin Compared to Antidepressant in Breakthrough Trial
A new trial has directly compared the antidepressant effects of psilocybin with a more classical antidepressant, and found that the two are matched in their mood-altering potential.
Cannabis Advertising Linked to Problematic Use in Teens, Study Claims
Teens who frequently see billboard or storefront advertising for recreational cannabis products are more likely to use the drug weekly and to have symptoms of cannabis use disorder, according to new research.
Young Cannabis Consumers Have Stiffer Arteries Than Non-smokers, Study Finds
Both the cannabis users and non-users showed similar resting heart rates and blood pressure levels, but the study’s authors are still concerned that even young cannabis consumers have an elevated risk of developing cardiovascular disease.
Could a Chemical Flip Produce a More Effective Ketamine-based Antidepressant?
Drug developers say that R-ketamine could potentially deliver a more targeted action with fewer side effects than its more popular chemical twin.
